Preview

Альманах клинической медицины

Расширенный поиск

Диагностическая и прогностическая значимость серологических маркеров воспалительных заболеваний кишечника (обзор литературы)

https://doi.org/10.18786/2072-0505-2020-48-061

Полный текст:

Аннотация

Диагностика воспалительных заболеваний кишечника (ВЗК) основана на комбинации клинических, эндоскопических, гистологических, лучевых и  лабораторных методов исследования. Однако традиционные методы не всегда обладают достаточной информативностью в диагностике ВЗК, особенно в случаях неклассифицируемого колита, что обусловливает необходимость расширения стандартных диагностических подходов. В  настоящее время активно ведется поиск неинвазивных серологических маркеров для ранней и дифференциальной диагностики ВЗК, а также оценки активности и  прогноза течения болезни Крона (БК) и  язвенного колита (ЯК). Среди показателей, вызывающих наибольший интерес, выделяют антитела к  Saccharomyces cerevisiae (англ. аntiSaccharomyces cerevisiae, ASCA), антинейтрофильные цитоплазматические антитела (англ. аntineutrophil cytoplasmic antibodies, ANCA), аутоантитела к  бокаловидным клеткам кишечника (англ. goblet cells antibodies, GAB) и  ацинарным клеткам поджелудочной железы (англ. pancreatic autoantibodies, PAB). Целью настоящего обзора стала оценка диагностической и  прогностической значимости ASCA, ANCA, GAB, PAB при БК и ЯК. В статье приведены обобщенные данные о  роли вышеуказанных антител в  нарушениях механизма иммунологической толерантности к  кишечной микрофлоре и  проницаемости кишечника при ВЗК. Обсуждаются результаты исследований ассоциаций ASCA с  осложненным фенотипом БК, ответом на генно-инженерную биологическую терапию, а  также необходимостью хирургических вмешательств. Представлены данные о связи ANCA с  риском прогрессирования левостороннего ЯК до распространенного (тотального) поражения толстой кишки, резистентного к  проведению гормональной терапии, а  антител к ДНК-лактоферриновым комплексам и протеиназе 3 – с первичным склерозирующим холангитом. Отмечено, что PAB могут выступать в качестве прогностического маркера илеоколита, перианальных поражений, внекишечных проявлений и  осложненного течения БК, а  GAB  – предиктора тотального ЯК с  хроническим постоянным течением. Подчеркивается высокая информативность комбинированного определения ASCA, ANCA, GAB и PAB по сравнению с изолированным выявлением аутоантител при проведении дифференциальной диагностики и прогнозирования БК и ЯК.

Об авторах

Д. А. Кузнецова
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России
Россия

Кузнецова Дарья Александровна – кандидат медицинских наук, врач клинической лабораторной диагностики лаборатории диагностики аутоиммунных заболеваний Научно-методического центра по молекулярной медицине

197022, г. Санкт-Петербург, ул. Льва Толстого, 6–8



С. В. Лапин
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России
Россия

Лапин Сергей Владимирович – кандидат медицинских наук, заведующий лабораторией диагностики аутоиммунных заболеваний Научно-методического центра по молекулярной медицине

197022, г. Санкт-Петербург, ул. Льва Толстого, 6–8



О. Б. Щукина
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России; СПбГУЗ «Городская клиническая больница № 31»
Россия

Щукина Оксана Борисовна – доктор медицинских наук, доцент кафедры общей врачебной практики (семейной медицины); руководитель Городского центра диагностики и лечения воспалительных заболеваний кишечника СПбГУЗ «Городская клиническая больница № 31»

197022, г. Санкт-Петербург, ул. Льва Толстого, 6–8; 
197110, г. СанктПетербург, пр-т Динамо, 3



Список литературы

1. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22. doi: 10.25122/jml-2018-0075.

2. Nuij VJ, Zelinkova Z, Rijk MC, Beukers R, Ouwendijk RJ, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ; Dutch Delta IBD Group. Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort). Inflamm Bowel Dis. 2013;19(10):2215– 22. doi: 10.1097/MIB.0b013e3182961626.

3. Lerner A. Autoantibody Profile in Inflammatory Bowel Disease. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. Autoantibodies. 3rd ed. Elsevier; 2014. p. 419–24.

4. Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, Yamauchi R, Fukunaga S, Torimura T. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304–10. doi: 10.3748/wjg.v22.i3.1304.

5. Baum LG, Cobb BA. The direct and indirect effects of glycans on immune function. Glycobiology. 2017;27(7):619–24. doi: 10.1093/glycob/cwx036.

6. Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, Lucidarme D, Camus D, Poulain D. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol. 1996;3(2):219–26.

7. Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, Mallet JM, Colombel JF, Poulain D. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology. 2006;130(6):1764–75. doi: 10.1053/j.gastro.2006.02.009.

8. Conrad K, Schößler W, Hiepe F, Fritzler MJ. Autoantibodies in Organ Specific Autoimmune Diseases – A Diagnostic Reference: Autoantigens, Autoantibodies, Autoimmunity. 2nd ed. Pabst, Wolfgang Science; 2017.

9. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120(4):827–33. doi: 10.1053/gast.2001.22546.

10. Klebl FH, Bataille F, Hofstädter F, Herfarth H, Schölmerich J, Rogler G. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int J Colorectal Dis. 2004;19(4):319–24. doi: 10.1007/s00384-003-0557-1.

11. Zhou G, Song Y, Yang W, Guo Y, Fang L, Chen Y, Liu Z. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease? Dig Dis. 2016;34(1–2):90–7. doi: 10.1159/000442934.

12. Hu C, Deng C, Zhang S, Song G, Li L, Li X, Wang L, Zhang F, Li Y. Clinical significance and prevalence of anti-Saccharomyces cerevisiae antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med. 2013;13(4):245–50. doi: 10.1007/s10238-012-0207-4.

13. Kotze LM, Nisihara RM, Utiyama SR, Kotze PG, Theiss PM, Olandoski M. Antibodies anti-Saccharomyces cerevisiae (ASCA) do not differentiate Crohn's disease from celiac disease. Arq Gastroenterol. 2010;47(3):242–5. doi: 10.1590/s0004-28032010000300006.

14. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10): 1394–403. doi: 10.1136/gut.2006.108043.

15. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J, Rogler G, Dotan N, Klebl F. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367–75. doi: 10.1002/ibd.21179.

16. Paul S, Boschetti G, Rinaudo-Gaujous M, Moreau A, Del Tedesco E, Bonneau J, Presles E, Mounsef F, Clavel L, Genin C, Flourié B, Phelip JM, Nancey S, Roblin X. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. J Crohns Colitis. 2015;9(6):445–51. doi: 10.1093/ecco-jcc/jjv063.

17. Kamm F, Strauch U, Degenhardt F, Lopez R, Kunst C, Rogler G, Franke A, Klebl F, Rieders F. Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. PLoS One. 2018;13(3):e0194222. doi: 10.1371/journal.pone.0194222. Erratum in: PLoS One. 2018;13(9):e0203709.

18. Sakly W, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci. 2008;53(7):1983–7. doi: 10.1007/s10620-007-0092-y.

19. Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A; Review Team. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J Clin Gastroenterol. 2016;50(10):803–18. doi: 10.1097/MCG.0000000000000660.

20. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144–64. doi: 10.1093/ecco-jcc/jjy113.

21. Kaul A, Hutfless S, Liu L, Bayless TM, Marohn MR, Li X. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18(10): 1872–84. doi: 10.1002/ibd.22862.

22. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54(9):1232–6. doi: 10.1136/gut.2004.060228.

23. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53(8):1117–22. doi: 10.1136/gut.2003.030734.

24. Müller S, Styner M, Seibold-Schmid B, Flogerzi B, Mähler M, Konrad A, Seibold F. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol. 2005;11(44):6988–94. doi: 10.3748/wjg.v11.i44.6988.

25. Huang L, Zhang J, Qiao Q, Gao M, Cao Q. Clinical significance of anti-sacchromyces cerevisiae antibody in Crohn’s disease: a single-center study. Int J Clin Exp Pathol. 2016;9(11):11978– 83.

26. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; Hungarian IBD Study Group, Lakatos PL. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103(3):665– 81. doi: 10.1111/j.1572-0241.2007.01652.x.

27. Щукина ОБ. Дифференциально-диагностические и прогностические критерии клинических форм болезни Крона [автореферат диссертации]. СПб.; 2017. 37 с.

28. Kaur M, Panikkath D, Yan X, Liu Z, Berel D, Li D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, Melmed GY, Haritunians T, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis. 2016;22(4):862–9. doi: 10.1097/MIB.0000000000000705.

29. Wang ZZ, Shi K, Peng J. Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype. Biomed Rep. 2017;6(4):401–10. doi: 10.3892/br.2017.860.

30. Lakatos PL, Sipeki N, Kovacs G, Palyu E, Norman GL, Shums Z, Golovics PA, Lovasz BD, Antal-Szalmas P, Papp M. Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn's Disease. J Crohns Colitis. 2015;9(10):891–8. doi: 10.1093/ecco-jcc/jjv127.

31. Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol. 2017;52(4):414–9. doi: 10.1080/00365521.2016.1259653.

32. Chandrakumar A, Georgy M, Agarwal P, 't Jong GW, El-Matary W. Anti-Saccharomyces cerevisiae Antibodies as a Prognostic Biomarker in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2019;69(1):82–7. doi: 10.1097/MPG.0000000000002311.

33. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14(3):348–54.e17. doi: 10.1016/j.cgh.2015.06.001.

34. Kyriakidi KS, Tsianos VE, Karvounis E, Christodoulou DK, Katsanos KH, Tsianos EV. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. Ann Gastroenterol. 2016;29(3):258–67. doi: 10.20524/aog.2016.0028.

35. Schulte-Pelkum J, Radice A, Norman GL, Lόpez Hoyos M, Lakos G, Buchner C, Musset L, Miyara M, Stinton L, Mahler M. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014;2014:185416. doi: 10.1155/2014/185416.

36. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000;68(3):1542–8. doi: 10.1128/iai.68.3.1542-1548.2000.

37. Харитонов АГ, Кондрашина ЭА, Барановский АЮ, Булгакова ТВ, Лапин СВ, Тотолян АА. Антитела к цитоплазме нейтрофилов как маркер неблагоприятного течения неспецифического язвенного колита. Медицинская иммунология. 2010;12(6):537–46. doi: 10.15789/1563-0625-2010-6-537-546.

38. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86(2):202–10. doi: 10.1016/s0091-6749(05)80067-3.

39. Rump JA, Schölmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Lüdemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990;181(4–5):406–13. doi: 10.1016/S0171-2985(11)80509-7.

40. Abu-Freha N, Badarna W, Sigal-Batikoff I, Abu Tailakh M, Etzion O, Elkrinawi J, Segal A, Mushkalo A, Fich A. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;18(1):153. doi: 10.1186/s12876-018-0884-x.

41. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13(14):2028–36. doi: 10.3748/wjg.v13.i14.2028.

42. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110(6):1810–9. doi: 10.1053/gast.1996.v110.pm8964407.

43. Lee WI, Subramaniam K, Hawkins CA, Randall KL. The significance of ANCA positivity in patients with inflammatory bowel disease. Pathology. 2019;51(6):634–9. doi: 10.1016/j.pathol.2019.07.002.

44. Yamamoto-Furusho JK, Takahashi-Monroy T, Vergara-Fernandez O, Reyes E, Uscanga L. Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. World J Gastroenterol. 2006;12(21):3406–9. doi: 10.3748/wjg.v12.i21.3406.

45. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71(5):431–6. doi: 10.4065/71.5.431.

46. Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105(8):1811–9. doi: 10.1038/ajg.2010.95.

47. Teegen B, Niemann S, Probst C, Schlumberger W, Stöcker W, Komorowski L. DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. Ann N Y Acad Sci. 2009;1173:161– 5. doi: 10.1111/j.1749-6632.2009.04752.x.

48. Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol. 2000;32(5): 734–41. doi: 10.1016/s0168-8278(00)80241-x.

49. Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease. PLoS One. 2018;13(12):e0208974. doi: 10.1371/journal.pone.0208974.

50. Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J, Bentow C, Shums Z, Forbes A, Norman GL. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267–73. doi: 10.1016/j.cca.2013.06.005.

51. Takedatsu H, Mitsuyama K, Fukunaga S, Yoshioka S, Yamauchi R, Mori A, Yamasaki H, Kuwaki K, Sakisaka H, Sakisaka S, Torimura T. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018;33(9):1603–7. doi: 10.1111/jgh.14140.

52. Stinton LM, Bentow C, Mahler M, Norman GL, Eksteen B, Mason AL, Kaplan GG, Lindkvist B, Hirschfield GM, Milkiewicz P, Cheung A, Janssen HL, Fritzler MJ. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One. 2014;9(11):e112877. doi: 10.1371/journal.pone.0112877.

53. Koch TR. P-ANCA for ulcerative colitis management – hype or hope? Am J Gastroenterol. 2002;97(2):485. doi: 10.1111/j.1572-0241.2002.05488.x.

54. Ooi CJ, Lim BL, Cheong WK, Ling AE, Ng HS. Antineutrophil cytoplasmic antibodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study. Ann Acad Med Singap. 2000;29(6):704–7.

55. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC; European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806. doi: 10.1097/MPG.0000000000000239.

56. Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 2013;23(1):28–42. doi: 10.11613/bm.2013.006.

57. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev. 2011;11(2):143–8. doi: 10.1016/j.autrev.2011.09.004.

58. Roggenbuck D, Vermeire S, Hoffman I, Reinhold D, Schierack P, Goihl A, von Arnim U, De Hertogh G, Polymeros D, Bogdanos DP, Bossuyt X. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease. Clin Chem Lab Med. 2015;53(9):1349–57. doi: 10.1515/cclm2014-0238.

59. Somma V, Ababneh H, Ababneh A, Gatti S, Romagnoli V, Bendia E, Conrad K, Bogdanos DP, Roggenbuck D, Ciarrocchi G. The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease. Gastroenterol Res Pract. 2013;2013:683824. doi: 10.1155/2013/683824.

60. Klebl FH, Bataille F, Huy C, Hofstädter F, Schölmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol. 2005;17(1):73–7. doi: 10.1097/00042737-200501000-00015.

61. Pavlidis P, Komorowski L, Teegen B, Liaskos C, Koutsoumpas AL, Smyk DS, Perricone C, Mytilinaiou MG, Stocker W, Forbes A, Bogdanos DP. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. Clin Chem Lab Med. 2016;54(2):249–56. doi: 10.1515/cclm-2015-0376.

62. Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1]. J Crohns Colitis. 2015;9(8):659–68. doi: 10.1093/ecco-jcc/jjv087.

63. Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M; Hungarian IBD Study Group. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009;15(3):365–74. doi: 10.1002/ibd.20778.

64. Deng C, Li W, Li J, Zhang S, Li Y. Diagnostic value of the antiglycoprotein-2 antibody for Crohn's disease: a PRISMA-compliant systematic review and meta-analysis. BMJ Open. 2017;7(6):e014843. doi: 10.1136/bmjopen-2016-014843.

65. Zhang S, Luo J, Wu Z, Roggenbuck D, Schierack P, Reinhold D, Li J, Zeng X, Zhang F, Qian J, Li Y. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease. Clin Transl Gastroenterol. 2018;9(2):e133. doi: 10.1038/ctg.2018.1.

66. Degenhardt F, Dirmeier A, Lopez R, Lang S, Kunst C, Roggenbuck D, Reinhold D, Szymczak S, Rogler G, Klebl F, Franke A, Rieder F. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease. Inflamm Bowel Dis. 2016;22(11):2648– 57. doi: 10.1097/MIB.0000000000000936.

67. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12(5): 319–30. doi: 10.1007/s11894-010-0131-2.

68. Alomair A, Alswayeh A, Alhazmi A, Alshammari A, Alsaffar S, Falamarzi A, Alothman M, Rayes L, Alkhathami M, Alhamidah A. Intestinal inflammation markers in inflammatory bowel disease. Int J Community Med Public Health. 2018;5(3):829–33. doi: 10.18203/2394-6040.ijcmph20180401.

69. Folwaczny C, Noehl N, Tschöp K, Endres SP, Heldwein W, Loeschke K, Fricke H. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology. 1997;113(1): 101–6. doi: 10.1016/s0016-5085(97)70085-4.

70. Hibi T, Ohara M, Kobayashi K, Brown WR, Toda K, Takaishi H, Hosoda Y, Hayashi A, Iwao Y, Watanabe M, et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut. 1994;35(2): 224–30. doi: 10.1136/gut.35.2.224.

71. Ye Y, Zhang L, Hu T, Chen W, Pang Z. Prospective value of serologic antibodies in Chinese patients with inflammation bowel disease. Int J Clin Exp Med. 2019;12(5):4860–9.

72. Kovacs M, Lakatos PL, Papp M, Jacobsen S, Nemes E, Polgar M, Solyom E, Bodi P, Horvath A, Muller KE, Molnar K, Szabo D, Cseh A, Dezsofi A, Arato A, Veres G. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55(4):429–35. doi: 10.1097/MPG.0b013e318256b516.

73. Homsak E, Micetić-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr. 2010;122 Suppl 2:19–25. doi: 10.1007/s00508-010-1344-y


Дополнительные файлы

1. Associations of serological markers to clinical and laboratory parameters in inflammatory bowel diseases
Тема
Тип Прочее
Посмотреть (310KB)    
Метаданные

Для цитирования:


Кузнецова Д.А., Лапин С.В., Щукина О.Б. Диагностическая и прогностическая значимость серологических маркеров воспалительных заболеваний кишечника (обзор литературы). Альманах клинической медицины. 2020;48(6):364-374. https://doi.org/10.18786/2072-0505-2020-48-061

For citation:


Kuznetsova D.А., Lapin S.V., Shchukina O.B. The diagnostic and prognostic value of serological markers of inflammatory bowel diseases (a literature review). Almanac of Clinical Medicine. 2020;48(6):364-374. (In Russ.) https://doi.org/10.18786/2072-0505-2020-48-061

Просмотров: 132


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-0505 (Print)
ISSN 2587-9294 (Online)